Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IONIS-APOCIIIRx, ISIS 304801, ApoC-III, Approach
Volanesorsen · 4 trials · 5 indications
Baseline for treatment-naïve group was defined as the average of open-label Day 1 pre-dose assessment and the last measurement prior to open-label Day 1. Baseline for CS6-volanesorsen and CS16-volanesorsen arm groups was defined as the average of index study Day 1 pre-dose assessment and the last measurement prior index study Day 1. The values at the Month 3 analysis time point were defined as the average of the Week 12 (Day 78) and Week 13 (Day 85) fasting assessments. The Month 6 analysis time point was at the end of Month 6, and the values were defined as the average of the Week 25 (Day 169) and Week 26 (Day 176) fasting assessments. The values at the Month 12 analysis time point were defined as the average of the Week 50 (Day 344) and Week 52 (Day 358) fasting assessments.
An adverse event (AE) was defined as any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered related to the investigational drug product. A TEAE was defined as any AE starting or getting worse on or after the first dose of the study drug.
ECG monitoring up to 24 hours post dose
| Arm | Type | Description |
|---|---|---|
| Treatment-naïve Group | EXPERIMENTAL | Treatment naïve group included combined group of ISIS 304801-CS7 (CS7-New) study participant and participant on placebo in index studies (ISIS 304801-CS6 \[NCT02211209\] and ISIS 304801-CS16 \[NCT02300233\]), were to receive 300 mg of volanesorsen as single SC once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following Week 52 visit, participants had option of participating in expanded access program or continuing treatment with 300 mg of volanesorsen as single SC once-weekly for up to additional 52 weeks (Weeks 53-104) and in France participants, up to additional 104 weeks for total of 156 weeks (Weeks 105 to Week 156) until expanded access program was approved and available in their country. Participants who were not participating in expanded access program were to enter 13-week post-treatment (PT) evaluation period and in France, participants not continuing treatment were to enter 26-week PT follow-up period. |
| CS6-Volanesorsen | EXPERIMENTAL | Participants with FCS rolling over from the ISIS 304801-CS6 (NCT02211209) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period. |
| CS16-Volanesorsen | EXPERIMENTAL | Participants with FCS rolling over from the ISIS 304801-CS16 (NCT02300233) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period. |
| Placebo | PLACEBO_COMPARATOR | Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks. |
| Volanesorsen 300 mg weekly | EXPERIMENTAL | Volanesorsen 300 mg administered subcutaneously once-weekly for 26 weeks. |
| Volanesorsen 300 mg biweekly, post Week 13 | EXPERIMENTAL | Volanesorsen 300 mg administered subcutaneously once-weekly for 13 weeks, then bi-weekly for 13 weeks. |
| Volanesorsen | EXPERIMENTAL | Volanesorsen 300 mg administered subcutaneously once-weekly for 52 weeks. |
| Volanesorsen, Intravenous (IV) | EXPERIMENTAL | 300 mg of volanesorsen (ISIS 304801) administered Intravenous (IV) single dose |
| Volanesorsen, Subcutaneous (SQ) | EXPERIMENTAL | 300 mg of volanesorsen (ISIS 304801) administered Subcutaneous (SQ) single dose |
| Moxifloxacin Hydrochloride | ACTIVE_COMPARATOR | Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose |
| Placebo Intravenous (IV) single dose | PLACEBO_COMPARATOR | Administered as normal saline (0.9% Sodium Chloride) |
| Placebo Subcutaneous (SC) single dose | PLACEBO_COMPARATOR | Administered as normal saline (0.9% Sodium Chloride) |
| Name | Type | Description |
|---|---|---|
| Volanesorsen | DRUG | 300 mg volanesorsen administered via SC injection. |
| Placebo | DRUG | Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks. |
| Moxifloxacin | DRUG | Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose |
Inclusion Criteria: * Must give written informed consent to participate in the study (signed and dated) and any authorization required by law. * Able and willing to participate in a 65-week study. Group 1 and 2: * Satisfactory completion of ISIS 304801-CS6 (NCT02211209) or ISIS 304801-CS16 (NCT02...
Volanesorsen is an investigational RNA therapy developed by Ionis Pharmaceuticals, Inc. (NASDAQ: IONS). It is designed to target apolipoprotein C-III (APOC3) and is being studied for cardiovascular and metabolic conditions, including familial chylomicronemia syndrome and hypertriglyceridemia.
Volanesorsen is being developed for the treatment of familial chylomicronemia syndrome and hypertriglyceridemia, as well as other cardiovascular abnormalities. It is not yet approved for any indication and remains under clinical investigation.
Volanesorsen targets apolipoprotein C-III (APOC3). It is an antisense inhibitor designed to reduce APOC3 production, which may lower triglyceride levels in patients with conditions such as familial chylomicronemia syndrome and hypertriglyceridemia.
Volanesorsen is being developed by Ionis Pharmaceuticals, Inc., which trades on the NASDAQ under the ticker IONS. The company is responsible for the clinical development of the drug.
Volanesorsen has completed Phase 3 clinical trials, including the APPROACH and COMPASS studies, and a Phase 1 cardiac repolarization study. It is not currently approved by the FDA and remains an investigational therapy.
Volanesorsen has been evaluated in completed trials including NCT02910635 (Phase 1 cardiac repolarization), NCT02658175 (Phase 3 open-label in familial chylomicronemia syndrome), NCT02300233 (Phase 3 COMPASS in hypertriglyceridemia), and NCT02211209 (Phase 3 APPROACH in familial chylomicronemia syndrome).
Yes, Volanesorsen was formerly known as ISIS-APOCIIIRx and IONIS-APOCIIIRx. These names refer to the same investigational drug developed by Ionis Pharmaceuticals.